表紙
市場調査レポート

造影剤の世界市場の予測 (〜2020年):製品 (ヨード・ガドリニウム・バリウム・マイクロバブル)・処置 (X線/CT・MRI・超音波)・用途 (放射線治療・IVR・IVC) 別

Contrast Media/Contrast Agents Market by Product (Iodinated, Gadolinium, Barium, Microbubble), by Procedure (X-Ray/CT, MRI, Ultrasound), by Application (Radiology, Interventional Radiology, Interventional Cardiology) - Global Forecasts to 2020

発行 MarketsandMarkets 商品コード 259150
出版日 ページ情報 英文 166 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
造影剤の世界市場の予測 (〜2020年):製品 (ヨード・ガドリニウム・バリウム・マイクロバブル)・処置 (X線/CT・MRI・超音波)・用途 (放射線治療・IVR・IVC) 別 Contrast Media/Contrast Agents Market by Product (Iodinated, Gadolinium, Barium, Microbubble), by Procedure (X-Ray/CT, MRI, Ultrasound), by Application (Radiology, Interventional Radiology, Interventional Cardiology) - Global Forecasts to 2020
出版日: 2015年07月06日 ページ情報: 英文 166 Pages
概要

造影剤の市場は、世界中の患者や放射線技師の要望を満たすべく、製品の開発や承認獲得などの面で過去数年にわたって様々な発展を進歩を遂げてきました。これらの発展が既存の造影剤の利用の改善や新たな造影剤の導入に繋がっています。

当レポートでは、世界の各種造影剤の市場について調査し、造影剤の種類と概要、市場成長への各種影響因子および市場機会の分析、製品タイプ・医療処置・投与経路・適応症・用途など各種区分別の市場分析および市場成長予測、地域および主要国の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 世界の造影剤市場
  • 製品・投与経路別市場
  • 適応症別市場

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 世界の造影剤市場:製品別

  • イントロダクション
  • バリウム造影剤
    • イントロダクション
    • メリット
    • デメリット
  • ヨード造影剤
    • イントロダクション
    • 各種タイプ
    • 制約
  • ガドリニウム造影剤
  • マイクロバブル造影剤

第7章 世界の造影剤市場:医療処置別

  • イントロダクション
  • X線/CT
  • MRI
  • 超音波

第8章 世界の造影剤市場:投与経路別

  • イントロダクション
  • 経口
  • 注射
  • 直腸注入
  • 尿道注入

第9章 世界の造影剤市場:適応症別

  • イントロダクション
  • 心臓血管疾患
  • 胃腸疾患
  • 神経疾患
  • 腎臓疾患
  • 筋骨格系疾患

第10章 世界の造影剤市場:用途別

  • イントロダクション
  • 放射線医学
  • IVR (インターベンショナルラジオロジー)
  • IVC (インターベンショナルカーディオロジー)

第11章 地域別市場

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • EU5カ国
    • その他
  • アジア太平洋
    • 日本
    • インド
    • 中国
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東
    • アフリカ

第12章 競合環境

  • 概要
  • 市場シェア分析
    • BAYER HEALTHCARE
    • GE HEALTHCARE
  • 競合状況・動向
    • 市場の発展 (製品の承認)
    • 合意・協力・戦略的提携・各種契約
    • 投資撤退 /投資
    • 拡張
    • その他

第13章 企業プロファイル

  • GE HEALTHCARE
  • BAYER HEALTHCARE
  • BRACCO IMAGING S.P.A. (A SUBSIDIARY OF BRACCO S.P.A.)
  • GUERBET GROUP
  • MALLINCKRODT PLC
  • LANTHEUS MEDICAL IMAGING
  • NANOPET PHARMA GMBH
  • CMC CONTRAST AB
  • TARGESON, INC. PHARMA CO., LTD.
  • 第一三共
  • SUBHRA PHARMA PRIVATE LIMITED
    • 概要
    • 財務動向
    • 製品・サービス
    • 戦略
    • 発展動向、など

第14章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 3577

Over the years, the contrast media/contrast agents market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide. These advancements have led to the improved use of many existing contrast agents as well as the introduction of new ones.

In 2015, the iodinated contrast media/contrast agents are expected to account for the largest share of the global contrast media/contrast agents market, among products; the injectable contrast media segment is expected to account for the largest share of the global contrast media/contrast agents market, among the routes of administration; the X-ray/CT segment is expected to dominate the global contrast media/contrast agents market, among procedures; cardiovascular disorders is expected to account for the largest share of the global contrast media/contrast agents market, among indications; and the radiology segment is expected to dominate the contrast media/contrast agents market, among applications.

In 2015, North America is estimated to be the largest market for contrast media/contrast agents, globally, followed by Europe, Asia-Pacific, and Rest of the World (RoW). In the coming years, the contrast media/contrast agents market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in this region can be attributed to the increasing research & development investments, expansion of international players, the increasing incidences of disease, and favorable regulatory frameworks.

The global contrast media/ contrast agents market has witnessed high competitive intensity in recent years, with Bayer Healthcare (Germany) and GE Healthcare (U.K.) being the leading market players. Other players include Guerbet Group (France), Bracco Imaging S.p.A. (Italy), Mallinckrodt PLC (Ireland), and Lantheus Medical Imaging (U.S.), among others. The players in this market have implemented various strategies to expand their global footprint and increase their market shares. The key strategies followed by most of the companies in the contrast media market include agreements, partnerships, strategic alliances, collaborations, corporate alliances/contracts; market development; and expansions; among others.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater share of the concerned market. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration:Comprehensive information on the product portfolios offered by the top players in the contrast media/contrast agents market - the report analyzes the contrast media/contrast agents market, on the basis of product, route of administration, procedure, indication, and application
  • Product Development/Innovation:Detailed insights on the upcoming technologies, research & development activities, product approvals, and new product launches in the contrast media/contrast agents market
  • Market Development:Comprehensive information about the lucrative emerging markets - the report analyzes the markets for various contrast media/contrast agents across regions
  • Market Diversification:Exhaustive information about new products, untapped regions, recent developments, and investments in the contrast media/contrast agents market
  • Competitive Assessment:In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the contrast media/contrast agents market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key industry insights
      • 2.2.2.2. Key data from primary sources
      • 2.2.2.3. Key insights from primary sources
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.3.1. MARKET FORECAST METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • 4.2. CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY PRODUCT AND ROUTE OF ADMINISTRATION
  • 4.3. CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY INDICATION (2015 VS. 2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Increase in demand for diagnostics & image guided procedures influences the sales of contrast media
      • 5.3.1.2. Increasing approvals for contrast agents
      • 5.3.1.3. Increase in the number of public and private diagnostic centers to improve diagnostic imaging services
      • 5.3.1.4. Rising number of cancer patients responsible for increasing the number of diagnostic procedures
      • 5.3.1.5. Increasing prevalence of diseases associated with the growth in the aging population is driving the demand of various diagnostic imaging modalities
      • 5.3.1.6. Improving healthcare infrastructure in emerging markets
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Risk associated with contrast agents
      • 5.3.2.2. Need for highly skilled professionals
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Strong product pipeline likely to boost the contrast media market
      • 5.3.3.2. Increasing research on contrast agent and their applications
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Development of gamma and neutron imaging solutions

6. GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. BARIUM- BASED CONTRAST MEDIA
    • 6.2.1. INTRODUCTION
    • 6.2.2. ADVANTAGES
    • 6.2.3. DISADVANTAGES
  • 6.3. IODINATED CONTRAST MEDIA
    • 6.3.1. INTRODUCTION
    • 6.3.2. TYPES
    • 6.3.3. LIMITATIONS
  • 6.4. GADOLINIUM BASED CONTRAST MEDIA
  • 6.5. MICROBUBBLES

7. GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY MEDICAL PROCEDURE

  • 7.1. INTRODUCTION
  • 7.2. X-RAY/CT
  • 7.3. MRI
  • 7.4. ULTRASOUND

8. GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1. INTRODUCTION
  • 8.2. ORAL CONTRAST MEDIA
  • 8.3. INJECTABLE CONTRAST MEDIA
  • 8.4. RECTAL CONTRAST MEDIA
  • 8.5. URETHRAL CONTRAST MEDIA

9. GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY INDICATION

  • 9.1. INTRODUCTION
  • 9.2. CARDIOVASCULAR DISORDERS
  • 9.3. ONCOLOGY
  • 9.4. GASTROINTESTINAL DISORDERS
  • 9.5. NEUROLOGICAL DISORDERS
  • 9.6. NEPHROLOGICAL DISORDERS
  • 9.7. MUSCULOSKELETAL DISORDERS

10. GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY APPLICATION

  • 10.1. INTRODUCTION
  • 10.2. RADIOLOGY
  • 10.3. INTERVENTIONAL RADIOLOGY
  • 10.4. INTERVENTIONAL CARDIOLOGY

11. CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
      • 11.2.1.1. Increase in the number of diagnostic imaging centers
      • 11.2.1.2. Increase in the ageing population and rising prevalence of chronic diseases in the U.S.
      • 11.2.1.3. Reimbursement cuts under Obama care
    • 11.2.2. CANADA
      • 11.2.2.1. High incidence rate of cancer, cardiovascular diseases and diabetes in Canada
      • 11.2.2.2. Increasing MRI and CT examinations and government funding to boost the Canadian market
  • 11.3. EUROPE
    • 11.3.1. EU5
      • 11.3.1.1. Increase in investment by market players
      • 11.3.1.2. Increasing incidence and prevalence of cancer
      • 11.3.1.3. Healthcare spending rises but remains weak in EU5 countries
      • 11.3.1.4. Shortage of medical imaging instruments/Scanners likely to hamper the U.K. market
    • 11.3.2. ROE
      • 11.3.2.1. Increase focus of market players in ROE Countries
      • 11.3.2.2. Increasing number of MRI and CT scanners
  • 11.4. ASIA-PACIFIC
    • 11.4.1. RISE IN THE AGEING POPULATION AND INCREASING CANCER INCIDENCE
    • 11.4.2. RISING NUMBER OF DIAGNOSTIC FACILITIES/PROCEDURES IN JAPAN
    • 11.4.3. EXPANSION OF INTERNATIONAL PLAYERS IN CHINA AND INDIA
    • 11.4.4. INCREASING R&D INVESTMENTS IN CHINA
    • 11.4.5. FAVOURABLE REGULATORY CHANGES TO INCREASE THE MARKET IN NEW ZEALAND AND AUSTRALIA
  • 11.5. REST OF THE WORLD
    • 11.5.1. LATIN AMERICA
    • 11.5.2. THE MIDDLE EAST
    • 11.5.3. AFRICA

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS, CONTRAST MEDIA/ CONTRAST AGENTS MARKET (2014)
    • 12.2.1. BAYER HEALTHCARE
    • 12.2.2. GE HEALTHCARE
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. MARKET DEVELOPMENT (PRODUCT APPROVALS)
    • 12.3.2. AGREEMENTS/ COLLABORATIONS/ PARTNERSHIPS/ STRATEGIC ALLIANCES/ CONTRACTS/ CORPORATE ALLIANCES
    • 12.3.3. DIVESTMENTS /INVESTMENTS
    • 12.3.4. EXPANSIONS
    • 12.3.5. OTHERS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. GE HEALTHCARE
  • 13.2. BAYER HEALTHCARE
  • 13.3. BRACCO IMAGING S.P.A. (A SUBSIDIARY OF BRACCO S.P.A.)
  • 13.4. GUERBET GROUP
  • 13.5. MALLINCKRODT PLC
  • 13.6. LANTHEUS MEDICAL IMAGING
  • 13.7. NANOPET PHARMA GMBH
  • 13.8. CMC CONTRAST AB
  • 13.9. TARGESON, INC. PHARMA CO., LTD.
  • 13.10. DAIICHI SANKYO
  • 13.11. SUBHRA PHARMA PRIVATE LIMITED

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. DISCUSSION GUIDE
  • 14.2. MORE COMPANY DEVELOPMENTS (2012-2015)
    • 14.2.1. GE HEALTHCARE
    • 14.2.2. BAYER HEALTHCARE
    • 14.2.3. BRACCO IMAGING S.P.A.
    • 14.2.4. GUERBET LLC
  • 14.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASING DEMAND FOR DIAGNOSTICS AND IMAGE GUIDED PROCEDURES COUPLED WITH RISING NUMBER OF APPROVALS FOR CONTRAST AGENTS/MEDIA ARE DRIVING THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • TABLE 2: RISK ASSOCIATED WITH CONTRAST AGENTS IS A MAJOR FACTOR RESTRAINING THE GROWTH OF THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • TABLE 3: STRONG PRODUCT PIPELINE AND INCREASING RESEARCH ACTIVITIES INFLUENCE THE GROWTH OF THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • TABLE 4: DEVELOPMENT OF GAMMA AND NEUTRON IMAGING SOLUTIONS POSE AS A CHALLENGE IN THE GROWTH OF THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • TABLE 5: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 6: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR BARIUM-BASED CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 7: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR IODINATED CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 8: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR GADOLINIUM BASED CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 9: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR MICROBUBBLE CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 10: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 11: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR X-RAY/CT, BY REGION, 2015-2020 ($MILLION)
  • TABLE 12: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR MRI, BY REGION, 2015-2020 ($MILLION)
  • TABLE 13: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR ULTRASOUND, BY REGION, 2013-2020 ($MILLION)
  • TABLE 14: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 15: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR ORAL CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 16: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR INJECTABLE CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 17: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR RECTAL CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 18: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR URETHRAL CONTRAST MEDIA, BY REGION, 2015-2020 ($MILLION)
  • TABLE 19: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 20: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2015-2020 ($MILLION)
  • TABLE 21: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR ONCOLOGY, BY REGION, 2015-2020 ($MILLION)
  • TABLE 22: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR GASTROINTESTINAL DISORDERS, BY REGION, 2015-2020 ($MILLION)
  • TABLE 23: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2015-2020 ($MILLION)
  • TABLE 24: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR NEPHROLOGICAL DISORDERS, BY REGION, 2015-2020 ($MILLION)
  • TABLE 25: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2015-2020 ($MILLION)
  • TABLE 26: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 27: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATIONS, 2015-2020 ($MILLION)
  • TABLE 28: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR RADIOLOGY, BY REGION, 2015-2020 ($MILLION)
  • TABLE 29: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2015-2020 ($MILLION)
  • TABLE 30: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2015-2020 ($MILLION)
  • TABLE 31: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY REGION, 2015-2020 ($MILLION)
  • TABLE 32: NORTH AMERICA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 33: NORTH AMERICA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 34: NORTH AMERICA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 35: NORTH AMERICA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 36: NORTH AMERICA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 37: U.S. : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 38: U.S: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020($MILLION)
  • TABLE 39: U.S: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 40: U.S: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 41: U.S: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 42: CANADA : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020($MILLION)
  • TABLE 43: CANADA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 44: CANADA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 45: CANADA: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 46: CANADA : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 47: EUROPE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 48: EUROPE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 49: EUROPE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 50: EUROPE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 51: EUROPE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 52: EU5 : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 53: EU5: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 54: EU5 : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 55: EU5 : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 56: EU5 : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE , BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 57: ROE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 58: ROE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 59: ROE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 60: ROE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 61: ROE : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 62: APAC : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020($MILLION)
  • TABLE 63: APAC : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 64: APAC : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 65: APAC : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 66: APAC : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 67: ROW : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PROCEDURE, 2015-2020 ($MILLION)
  • TABLE 68: ROW : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY PRODUCT, 2015-2020 ($MILLION)
  • TABLE 69: ROW : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2015-2020 ($MILLION)
  • TABLE 70: ROW : CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY INDICATION, 2015-2020 ($MILLION)
  • TABLE 71: ROW: CONTRAST MEDIA/ CONTRAST AGENTS MARKET SIZE, BY APPLICATION, 2015-2020 ($MILLION)
  • TABLE 72: MARKET DEVELOPMENT (PRODUCT APPROVALS), 2012-2015
  • TABLE 73: AGREEMENTS/ PARTNERSHIPS/ STRATEGIC ALLIANCES/ COLLABORATIONS/ CORPORATE ALLIANCES/CONTRACTS 2012-2015
  • TABLE 74: DIVESTMENTS/INVESTMENTS 2012-2015
  • TABLE 75: EXPANSIONS 2012-2015
  • TABLE 76: OTHER STRATEGIES 2012-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: SAMPLING FRAME: PRIMARY RESEARCH
  • FIGURE 3: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: MARKET FORECAST METHODOLOGY
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: ULTRASOUND MARKET TO WITNESS THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 9: THE INJECTABLE ROUTE OF ADMINISTRATION SEGMENT IS EXPECTED TO DOMINATE THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET THROUGHOUT THE FORECAST PERIOD
  • FIGURE 10: INTERVENTIONAL CARDIOLOGY IS EXPECTED TO GROW AT HIGHEST CAGR FOR THE FORECAST PERIOD
  • FIGURE 11: ASIA-PACIFIC IS SLATED TO WITNESS THE HIGHEST GROWTH IN THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET IN THE FORECAST PERIOD
  • FIGURE 12: CONTRAST MEDIA/ CONTRAST AGENTS MARKET: MARKET OVERVIEW
  • FIGURE 13: INJECTABLE CONTRAST MEDIA- THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET IN 2015
  • FIGURE 14: ASIA TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 15: CARDIOVASCULAR DISORDERS WOULD COMMAND THE LARGEST SHARE DURING THE FORECAST PERIOD
  • FIGURE 16: CONTRAST MEDIA MEDICAL IMAGNG MARKET SEGMENTATION
  • FIGURE 17: DRIVERS, RESTRAINTS, CHALLENGES, & OPPORTUNITIES
  • FIGURE 18: MICROBUBBLE CONTRAST MEDIA IS THE FASTEST GROWING PRODUCT SEGMENT OF THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 19: X-RAY/CT ACCOUNTS FOR THE LARGEST SHARE OF THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 20: INJECTABLE CONTRAST MEDIA IS THE LARGEST AND FASTEST GROWING SEGMENT IN THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 21: CARDIOVASCULAR DISORDERS SEGMENT ACCOUNTS FOR THE LARGEST SHARE OF THE CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 22: RADIOLOGY IS LARGEST APPLICATION SEGMENT IN CONTRAST MEDIA/CONTRAST REAGENTS MARKET
  • FIGURE 23: NORTH AMERICA COMMANDED THE LARGEST SHARE OF CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 24: U.S. COMMANDED THE LARGEST SHARE OF NORTH AMERICAN CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 25: EU5 REGION DOMINATES THE EUROPEAN CONTRAST MEDIA/ CONTRAST AGENTS MARKET
  • FIGURE 26: MARKET DEVELOPMENT ( PRODUCT APPROVALS) WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS
  • FIGURE 27: GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET SHARE, BY KEY PLAYER, 2014
  • FIGURE 28: BATTLE FOR MARKET SHARE: MARKET DEVELOPMENT (PRODUCT APPROVALS) WAS THE KEY STRATEGY (2012-2015)
  • FIGURE 29: KEY PLAYERS FOCUSING ON MARKET DEVELOPMENT (PRODUCT APPROVALS), 2012-2015
  • FIGURE 30: KEY PLAYERS FOCUSING ON AGREEMENTS/ COLLABORATIONS/ PARTNERSHIPS/ STRATEGIC ALLIANCES/ CONTRACTS /CORPORATE ALLIANCES, 2012-2015
  • FIGURE 31: KEY PLAYERS FOCUSING ON DIVESTMENTS/ INVESTMENTS, 2012-2015
  • FIGURE 32: KEY PLAYERS FOCUSING ON EXPANSIONS, 2012-2015
  • FIGURE 33: KEY PLAYERS FOCUSING ON OTHER STRATEGIES, 2012-2015
  • FIGURE 34: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 35: BAYER HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 36: GUERBET GROUP: COMPANY SNAPSHOT
  • FIGURE 37: MALLINCKRODT PLC: COMPANY SNAPSHOT
  • FIGURE 38: LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT
  • FIGURE 39: DAIICHI SANKYO: COMPANY SNAPSHOT
Back to Top